Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Survival improvement for patients with metastatic colorectal cancer over twenty years

Open access

Abstract

Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the incremental change in survival for metastatic CRC patients not treated on trial has not yet been quantified. We performed a retrospective review of 1420 patients with de novo metastatic CRC who received their primary treatment at the University of Texas M.D. Anderson Cancer Center (UTMDACC) from 2004 through 2019. Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months). Likewise, 5-year survival rate has increased from 15.7% for patients diagnosed from 2004 to 2006 to 26% for those diagnosed from 2013 to 2015. Notably, survival improved for patients with BRAF V600E mutant as well as microsatellite unstable (MSI-H) tumors. Multivariate regression analysis identified surgical resection of liver metastasis (HR = 0.26, 95% CI, 0.19–0.37), use of immunotherapy (HR = 0.44, 95% CI, 0.29–0.67) and use of third line chemotherapy (regorafenib or trifluridine/tipiracil, HR = 0.74, 95% CI, 0.58–0.95), but not year of diagnosis (HR = 0.99, 95% CI, 0.98–1), as associated with better survival, suggesting that increased use of these therapies are the drivers of the observed improvement in survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41698-023-00353-4

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Overall survival for patients with metastatic colorectal cancer treated at M.D. Anderson Cancer Center by year of diagnosis. a Kaplan–Meier overall survival curves for metastatic CRC patients group by year of diagnosis, log-rank p-value comparing all curves <0.0001. b Five-year survival rate according to year of diagnosis. For 2016 to 2019, this has not yet reached.
Fig. 1 Overall survival for patients with metastatic colorectal cancer treated at M.D. Anderson Cancer Center by year of diagnosis. a Kaplan–Meier overall survival curves for metastatic CRC patients group by year of diagnosis, log-rank p-value comparing all curves <0.0001. b Five-year survival rate according to year of diagnosis. For 2016 to 2019, this has not yet reached.CC BY · PubMed Central
Fig. 2 Hepatic Resection of Liver Metastasis. a Percentage of patients undergoing liver resection by date of diagnosis, note increase after 2014. b Overall survival by landmark analysis of patients with metastatic colorectal cancer diagnosed between 2004 and 2019, error bars represent 95% CI, Log-rank p < 0.0001.
Fig. 2 Hepatic Resection of Liver Metastasis. a Percentage of patients undergoing liver resection by date of diagnosis, note increase after 2014. b Overall survival by landmark analysis of patients with metastatic colorectal cancer diagnosed between 2004 and 2019, error bars represent 95% CI, Log-rank p < 0.0001.CC BY · PubMed Central
Fig. 3 Chemotherapy utilization changes over time. a The percentage of each chemotherapy administered to patients between 2004 and 2019, binned by year, note use of novel chemotherapeutics increased after 2012. b Percentage of patients treated with novel drugs, IO Immunotherapy, Tri/TI Trifluridine/Tipiracil.
Fig. 3 Chemotherapy utilization changes over time. a The percentage of each chemotherapy administered to patients between 2004 and 2019, binned by year, note use of novel chemotherapeutics increased after 2012. b Percentage of patients treated with novel drugs, IO Immunotherapy, Tri/TI Trifluridine/Tipiracil.CC BY · PubMed Central
Fig. 4 Overall survival for patients with metastatic colorectal cancer with either BRAF mutation or microsatellite instability. a Kaplan–Meier overall survival curves for patients with BRAF mutation before and after 2014, error bars represent 95% CI, log-rank p = 0.04. Median overall survival (b) and three-year survival rate (c) for patients with BRAF mutation, note improvement after 2015. Kaplan–Meier overall survival curve (d), median overall survival, error bars represent 95% CI, log-rank p = 0.008 (e) and three-year survival rate (f) for MSI-H patients, note improvement after 2015 where median overall survival is not-yet-reached. Number of patients indicated above bar plot.
Fig. 4 Overall survival for patients with metastatic colorectal cancer with either BRAF mutation or microsatellite instability. a Kaplan–Meier overall survival curves for patients with BRAF mutation before and after 2014, error bars represent 95% CI, log-rank p = 0.04. Median overall survival (b) and three-year survival rate (c) for patients with BRAF mutation, note improvement after 2015. Kaplan–Meier overall survival curve (d), median overall survival, error bars represent 95% CI, log-rank p = 0.008 (e) and three-year survival rate (f) for MSI-H patients, note improvement after 2015 where median overall survival is not-yet-reached. Number of patients indicated above bar plot.CC BY · PubMed Central
Fig. 5 Overall survival for patients with metastatic colorectal according to primary tumor location. a Kaplan–Meier overall survival curves comparing patients based on primary site location, log-rank p < 0.0001. Kaplan–Meier overall survival curves showing the change in overall survival of patients with left (b) and right (c) sided tumors. d Median overall survival of patients according to tumor location binned by time of diagnosis. e Five-year survival rate according to tumor location binned by time of diagnosis. For 2016 to 2019, this has not yet reached.
Fig. 5 Overall survival for patients with metastatic colorectal according to primary tumor location. a Kaplan–Meier overall survival curves comparing patients based on primary site location, log-rank p < 0.0001. Kaplan–Meier overall survival curves showing the change in overall survival of patients with left (b) and right (c) sided tumors. d Median overall survival of patients according to tumor location binned by time of diagnosis. e Five-year survival rate according to tumor location binned by time of diagnosis. For 2016 to 2019, this has not yet reached.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Research works printed but not linked: 1

  1. Abdalla, E. K. et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann. Surg. 239, 818–825 (2004). · DOI · Paper page

Cited by

See all 206

Metadata

Authors
Zeineddine, F. A., Zeineddine, M. A., Yousef, A., Gu, Y., Chowdhury, S., Dasari, A., Huey, R. W., Johnson, B., Kee, B., Lee, M. S., Morelli, M. P., Morris, V. K., Overman, M. J., Parseghian, C., Raghav, K., Willis, J., Wolff, R. A., Kawaguchi, Y., Vauthey, J.-N., Sun, R., Kopetz, S., & Shen, J. P.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Shen, John Paul
Venue
npj Precision Oncology
Published
2023-02-13
Volume
7
Issue
1
Pages
16-16
ISSN
2397-768X (ISSN-L)
OpenAlex
W4320481117
Cited by
192
References
65
Citations by year
2026: 56 · 2025: 68 · 2024: 51 · 2023: 16
FWCI
23.30
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Precision Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Cancer Prevention and Research Institute of Texas
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (SPORE P50CA221707)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords
metastatic colorectal cancer, survival improvement, hepatectomy, immunotherapy, regorafenib, trifluridine/tipiracil, BRAF V600E mutation, microsatellite instability, third-line chemotherapy, year of diagnosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival improvement for patients with metastatic colorectal cancer over twenty years. https://app.cochat.ai/papers/10.1038/s41698-023-00353-4
The paper
Zeineddine, F. A., Zeineddine, M. A., Yousef, A., Gu, Y., Chowdhury, S., Dasari, A., Huey, R. W., Johnson, B., Kee, B., Lee, M. S., Morelli, M. P., Morris, V. K., Overman, M. J., Parseghian, C., Raghav, K., Willis, J., Wolff, R. A., Kawaguchi, Y., Vauthey, J.-N., . . . Shen, J. P. (2023). Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precision Oncology. https://doi.org/10.1038/s41698-023-00353-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.